Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F16%3A00092817" target="_blank" >RIV/00216224:14110/16:00092817 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1007/978-3-319-27601-4_42" target="_blank" >http://dx.doi.org/10.1007/978-3-319-27601-4_42</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/978-3-319-27601-4_42" target="_blank" >10.1007/978-3-319-27601-4_42</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Popis výsledku v původním jazyce

Most patients with recurrent or metastatic head and neck squamous cell cancers qualify for palliative treatment. The management of these patients includes supportive care only, mono- or multiagent chemotherapy, and more recently targeted therapies. While platinum-based combinations are superior to single-agent therapies in terms of response rate, they are more toxic and so far have not shown to lead to meaningful survival benefit. Attempts to improve on this by using other or additional cytotoxic drugs were unsuccessful in the last 30 years. It was therefore an urgent need to investigate the efficacy of novel anticancer therapies that specifically target the tumor cells in such patients. A recent randomized trial showed that adding cetuximab, an EGFR-directed monoclonal antibody, to a standard platinum-based chemotherapy regimen led to an important survival benefit.

Název v anglickém jazyce

Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Popis výsledku anglicky

Most patients with recurrent or metastatic head and neck squamous cell cancers qualify for palliative treatment. The management of these patients includes supportive care only, mono- or multiagent chemotherapy, and more recently targeted therapies. While platinum-based combinations are superior to single-agent therapies in terms of response rate, they are more toxic and so far have not shown to lead to meaningful survival benefit. Attempts to improve on this by using other or additional cytotoxic drugs were unsuccessful in the last 30 years. It was therefore an urgent need to investigate the efficacy of novel anticancer therapies that specifically target the tumor cells in such patients. A recent randomized trial showed that adding cetuximab, an EGFR-directed monoclonal antibody, to a standard platinum-based chemotherapy regimen led to an important survival benefit.

Druh

C - Kapitola v odborné knize

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Head and Neck Cancer

ISBN

9783319275994

Počet stran výsledku

19

Strana od-do

711-729

Počet stran knihy

878

Název nakladatele

Springer International Publishing

Místo vydání

Switzerland

Kód UT WoS kapitoly

—